| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3220 |
| Trial ID | NCT05602961 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | GLB-COV2-043;BNT162b2|COMIRNATY|Tozinameran |
| Location approved | NULL;UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Phase | Phase1|Phase2 |
| Recruitment status | Withdrawn |
| Title | A Phase I/II Partially Randomized, Active-controlled Observer-blind, Dose-selection, Safety and Immunogenicity Study of GLB-COV2-043, an mRNA Vaccine Candidate Against SARS-CoV-2, Administered as a Single-vaccination Booster to Previously Vaccinated Adults |
| Year | 2023 |
| Country | United States |
| Company sponsor | GreenLight Biosciences, Inc. |
| Other ID(s) | GLB-003 |
| Vector information | |||
|
|||
| Cohort1: BNT162b2_dose level 1_GLB-COV2-043_dose level 1 | |||||||||
|
|||||||||
| Cohort2: BNT162b2_dose level 1_GLB-COV2-043_dose level 2 | |||||||||
|
|||||||||
| Cohort3: BNT162b2_dose level 2_GLB-COV2-043_dose level 2 | |||||||||
|
|||||||||
| Cohort4: BNT162b2_dose level 3_GLB-COV2-043_dose level 2 | |||||||||
|
|||||||||